IL261998B2 - Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors - Google Patents

Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Info

Publication number
IL261998B2
IL261998B2 IL261998A IL26199818A IL261998B2 IL 261998 B2 IL261998 B2 IL 261998B2 IL 261998 A IL261998 A IL 261998A IL 26199818 A IL26199818 A IL 26199818A IL 261998 B2 IL261998 B2 IL 261998B2
Authority
IL
Israel
Prior art keywords
inhibitor
chemokine receptor
receptor antagonist
ccr1
group
Prior art date
Application number
IL261998A
Other languages
English (en)
Hebrew (he)
Other versions
IL261998B (en
IL261998A (en
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of IL261998A publication Critical patent/IL261998A/en
Publication of IL261998B publication Critical patent/IL261998B/en
Publication of IL261998B2 publication Critical patent/IL261998B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL261998A 2016-04-07 2017-04-06 Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors IL261998B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319689P 2016-04-07 2016-04-07
PCT/US2017/026290 WO2017176965A1 (en) 2016-04-07 2017-04-06 Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Publications (3)

Publication Number Publication Date
IL261998A IL261998A (en) 2018-10-31
IL261998B IL261998B (en) 2022-11-01
IL261998B2 true IL261998B2 (en) 2023-03-01

Family

ID=59999231

Family Applications (1)

Application Number Title Priority Date Filing Date
IL261998A IL261998B2 (en) 2016-04-07 2017-04-06 Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Country Status (19)

Country Link
US (2) US10568870B2 (OSRAM)
EP (1) EP3439653B1 (OSRAM)
JP (2) JP7539231B2 (OSRAM)
KR (1) KR102370704B1 (OSRAM)
CN (1) CN109310677A (OSRAM)
AR (1) AR108202A1 (OSRAM)
AU (1) AU2017246460B2 (OSRAM)
BR (1) BR112018070361A2 (OSRAM)
DK (1) DK3439653T3 (OSRAM)
ES (1) ES2864148T3 (OSRAM)
IL (1) IL261998B2 (OSRAM)
MX (1) MX384929B (OSRAM)
PL (1) PL3439653T3 (OSRAM)
PT (1) PT3439653T (OSRAM)
RU (1) RU2745195C2 (OSRAM)
SG (1) SG11201808626WA (OSRAM)
TW (1) TWI808938B (OSRAM)
WO (1) WO2017176965A1 (OSRAM)
ZA (1) ZA201806633B (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
PL3439653T3 (pl) 2016-04-07 2021-07-05 Chemocentryx, Inc. Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
ES2979332T3 (es) 2016-06-27 2024-09-25 Chemocentryx Inc Compuestos inmunomoduladores
RU2730984C1 (ru) * 2017-03-29 2020-08-26 Сионоги Энд Ко., Лтд. Фармацевтическая композиция для лечения злокачественного новообразования
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
WO2019126690A1 (en) * 2017-12-22 2019-06-27 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
MA51232A (fr) 2018-02-22 2020-10-07 Chemocentryx Inc Indane-amines utiles en tant qu'antagonistes de pd-l1
US12168049B2 (en) 2018-03-08 2024-12-17 Codagenix Inc. Attenuated flaviviruses
WO2019240871A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with s-equol
EP3843718A1 (en) 2018-06-15 2021-07-07 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
MA53506A (fr) * 2018-08-29 2021-07-07 Chemocentryx Inc Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
WO2020061376A2 (en) 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2020102375A1 (en) 2018-11-14 2020-05-22 Regeneron Pharmaceuticals, Inc. Intralesional administration of pd-1 inhibitors for treating skin cancer
AU2020228296B2 (en) 2019-02-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Administration of PD-1 inhibitors for treating skin cancer
CN113677707A (zh) 2019-03-06 2021-11-19 瑞泽恩制药公司 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
BR112022001985A2 (pt) * 2019-09-11 2022-05-10 Boehringer Ingelheim Io Canada Inc Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina
GB201918692D0 (en) 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer
WO2021133476A1 (en) * 2019-12-24 2021-07-01 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
AU2021280245A1 (en) 2020-05-26 2022-12-08 Regeneron Pharmaceuticals, Inc. Methods of treating cervical cancer by administering a PD-1 inhibitor
MA71214A (fr) 2020-08-26 2025-04-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
KR20230061499A (ko) 2020-09-03 2023-05-08 리제너론 파마슈티칼스 인코포레이티드 Pd-1 저해제 투여에 의한 암 통증 치료 방법
EP4228627A4 (en) * 2020-10-13 2024-11-06 Board of Regents, The University of Texas System COMBINATORIAL IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATIC DUCT ADENOCARCINOMA
EP4313123A1 (en) 2021-03-23 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
EP4373505A1 (en) 2021-07-19 2024-05-29 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
JP2025506696A (ja) 2022-02-17 2025-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんを処置するためのチェックポイント阻害剤と腫瘍溶解性ウイルスの組合せ
WO2023230220A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
US20250114468A1 (en) 2023-10-09 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058341A1 (en) * 2005-06-22 2008-03-06 Penglie Zhang Azaindazole compounds and methods of use
WO2010030815A1 (en) * 2008-09-11 2010-03-18 Chemocentryx, Inc. 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines
US20140171420A1 (en) * 2012-12-07 2014-06-19 Chemocentryx, Inc. Diazole lactams

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
DE19539091A1 (de) 1995-10-20 1997-04-24 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
PL1618092T3 (pl) 2003-05-01 2011-02-28 Bristol Myers Squibb Co Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy
CA2609051A1 (en) 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
PL1906965T3 (pl) 2005-06-22 2015-10-30 Chemocentryx Inc Związki azaindazolowe i sposoby zastosowania
FR2887450B1 (fr) 2005-06-23 2007-08-24 Rhodia Chimie Sa Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
WO2007026834A1 (ja) 2005-09-01 2007-03-08 Kumiai Chemical Industry Co., Ltd. ピラゾール誘導体及び農園芸用除草剤
WO2007044804A2 (en) 2005-10-11 2007-04-19 Chemocentryx, Inc. Piperidine derivatives and methods of use
US20090252779A1 (en) 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
CA2675511A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
WO2008072724A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. ピラゾール誘導体
US7786157B2 (en) 2007-03-16 2010-08-31 Chemocentryx, Inc. OXO-imidazolidines as modulators of chemokine receptors
NZ581405A (en) 2007-05-22 2011-06-30 Chemocentryx Inc 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
CA2691468C (en) 2007-06-22 2017-05-09 Hydra Biosciences, Inc. Substituted xanthine compounds and methods to treat diseases mediated by trpa1
CA2705502C (en) 2007-11-13 2016-01-26 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
US20120108614A1 (en) 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
MX2014011353A (es) 2012-03-29 2014-12-05 Aurigene Discovery Tech Ltd Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana.
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP6339573B2 (ja) * 2012-08-27 2018-06-06 ケモセントリックス，インコーポレイティド ケモカイン受容体のアンタゴニスト
EP2935227B1 (en) 2012-12-21 2017-09-13 ChemoCentryx, Inc. Diazole amides as ccr1 receptor antagonists
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX384142B (es) * 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
EP3035964B1 (en) 2013-08-20 2020-09-23 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
CA2923184A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
HUE048874T2 (hu) 2013-09-06 2020-08-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazol-származékok, mint immunmodulátorok
SMT201800421T1 (it) 2013-09-06 2018-09-13 Aurigene Discovery Tech Ltd Derivati di 1,3,4-ossadiazolo e 1,3,4-tiadiazolo come immunomodulatori
HUE039012T2 (hu) 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd Gyûrûs peptidomimetikus vegyületek, mint immunomodulátorok
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CA2950423A1 (en) * 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2016011160A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
EA201791634A1 (ru) 2015-03-10 2018-03-30 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
AU2016230793B2 (en) 2015-03-10 2021-03-25 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
EA201791628A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед Терапевтические циклические соединения в качестве иммуномодуляторов
EP3267999A4 (en) 2015-03-10 2018-07-25 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
CA2979161A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10110466B2 (en) * 2015-11-23 2018-10-23 Tyco Electronics Subsea Communications Llc Optical communication system with distributed wet plant manager
PL3439653T3 (pl) 2016-04-07 2021-07-05 Chemocentryx, Inc. Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058341A1 (en) * 2005-06-22 2008-03-06 Penglie Zhang Azaindazole compounds and methods of use
WO2010030815A1 (en) * 2008-09-11 2010-03-18 Chemocentryx, Inc. 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines
US20140171420A1 (en) * 2012-12-07 2014-06-19 Chemocentryx, Inc. Diazole lactams

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMANISHI, JUNZO, ET AL., PD-1/PD-L1 BLOCKADE IN CANCER TREATMENT: PERSPECTIVES AND ISSUES., 31 December 2016 (2016-12-31) *
JUNG, HEIYOUN, ET AL., COMBINATION THERAPY OF CHEMOKINE RECEPTOR INHIBITION PLUS PDL-1 BLOCKADE POTENTIATES ANTI-TUMOR EFFECTS IN A MURINE MODEL OF BREAST CANCER., 31 December 2015 (2015-12-31) *

Also Published As

Publication number Publication date
KR102370704B1 (ko) 2022-03-03
US10568870B2 (en) 2020-02-25
AU2017246460A1 (en) 2018-10-25
CN109310677A (zh) 2019-02-05
IL261998B (en) 2022-11-01
BR112018070361A2 (pt) 2019-01-29
DK3439653T3 (da) 2021-03-29
RU2018138828A3 (OSRAM) 2020-08-12
RU2018138828A (ru) 2020-05-15
WO2017176965A1 (en) 2017-10-12
MX384929B (es) 2025-03-14
NZ746960A (en) 2025-05-30
JP7539231B2 (ja) 2024-08-23
IL261998A (en) 2018-10-31
CA3019391A1 (en) 2017-10-12
US20170290808A1 (en) 2017-10-12
ZA201806633B (en) 2021-04-28
PT3439653T (pt) 2021-03-25
JP2022130424A (ja) 2022-09-06
SG11201808626WA (en) 2018-10-30
JP2019510832A (ja) 2019-04-18
AU2017246460B2 (en) 2021-04-22
EP3439653A4 (en) 2019-12-04
US20200289472A1 (en) 2020-09-17
JP7611189B2 (ja) 2025-01-09
ES2864148T3 (es) 2021-10-13
KR20190020291A (ko) 2019-02-28
AR108202A1 (es) 2018-07-25
EP3439653A1 (en) 2019-02-13
MX2018012132A (es) 2019-03-28
RU2745195C2 (ru) 2021-03-22
PL3439653T3 (pl) 2021-07-05
TW201801724A (zh) 2018-01-16
US11744822B2 (en) 2023-09-05
TWI808938B (zh) 2023-07-21
EP3439653B1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
JP7611189B2 (ja) Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
AU2024204212B2 (en) Combination therapy using a Chemokine Receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
US20240285593A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
CA2909625A1 (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA3019391C (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK40004572B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
RU2796863C2 (ru) Комбинированная терапия с использованием антагониста хемокинового рецептора 2 (CCR2) и ингибитора PD-1/PD-L1
BR122024013223A2 (pt) Composição de antagonistas do ccr1 e inibidores de pd-1 ou inibidores de pd-l1, kit e seus usos
WO2020191240A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor